Arsanis Inc (NASDAQ:ASNS) reported that the “USPTO” issued a patent to the firm for its product named ASN100. This patent allows intellectual property protection in the U.S. through 2033. ASN100 marks as a combination of two fully human mAbs that together neutralize the 6 cytotoxins major to S. aureus pneumonia pathogenesis, counting toxins that destroy human immune cells and damage lung tissue.
René Russo, the CEO of Arsanis, expressed that ASN100 marks as a first-in-class mAb therapeutic intended to exactly disarm a clinically vital pathogen without bringing antibiotic resistance, a mechanism-of-action which reinforces company’s unique approach to anti-infective advancement. The cross-reactive feature of the ASN100 antibodies allows them to neutralize and bind numerous S. aureus toxins simultaneously, which they consider considerably differentiates ASN100 from other advancement stage mAbs that offset only a single toxin.
Michael Gray, who is the Chief Financial Officer and Chief Operating Officer of Arsanis, expressed that the USPTO granting of this vital patent shadows comparable patents for the composition-of-matter for the cross-reactive antibodies, counting patent grants given by the European Patent Office back in 2015, and by the IP Australia and Japan Patent Office in 2017. They intend to continue their initiatives to strengthen their intellectual property portfolio for ASN100 as well as other pipeline programs.
ASN100 marks as a combination of two co-given fully human mAbs, ASN-2 and ASN-1, that together neutralize the 6 cytotoxins major to S. aureus pneumonia pathogenesis. As per the update, ASN-1 neutralizes Hla, a cytotoxin that harms lung epithelial cells, and 4 leukocidins, cytotoxins that damage human immune cells: gamma-hemolysin CB (HlgCB), gamma-hemolysin AB (HlgAB), leukocidin ED (LukED) and Panton-Valentine leukocidin (PVL). ASN-2 neutralizes LukGH, a mainly potent human cytotoxin also accountable for the damage of human immune cells. Arsanis reported that ASN100 is presently being assessed in a Phase II clinical study targeting S. aureus pneumonia.